Ampio Pharmaceuticals

Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of immunomodulatory therapies for the treatment of pain from osteoarthritis in the United States. Its product pipeline includes AP-013, an intra-articular injection, which is in phase III clinical trial for the treatment of osteoarthritis of the knee; AP-017, an intravenous ampion treatment that is in Phase II clinical trial to treat adult COVID-19 patients requiring oxygen supplementation; AP-019, an Inhaled Ampion treatment, which is in Phase II clinical trial for the treatment of Adults with Respiratory Distress Due to COVID-19; and AP-018 that is in Phase I clinical trial to treat patients with prolonged respiratory symptoms due to COVID-19. The company is headquartered in Englewood, Colorado.

At Ampio Pharmaceuticals, our mission is to provide novel, safe, and effective treatments to improve the lives of those suffering from chronic and debilitating diseases.

We strive to be a leader in the development of novel treatments and medical breakthroughs in the areas of pain management, diabetes, renewable resources, and regenerative medicine.

Over the past 15 years, Ampio has received recognition and awards from organizations such as The International Association for the Study of Pain, The Federation of American Societies for Experimental Biology, and The American Heart Association.